Patents by Inventor Patrick Bäuerle
Patrick Bäuerle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080044413Abstract: The present invention relates to bispecific single chain antibodies comprising a first binding domain that immunospecifically binds to the T-cell antigen CD3 and a second binding domain that immunospecifically binds to the EphA2 receptor. Such bispecific single chain antibodies are encompassed by the term “EphA2-BiTEs.” The present invention further relates to methods and compositions designed for the treatment, prevention and/or management of disorders associated with aberrant expression and/or activity of EphA2. Such disorders include, but are not limited to, cancer, non-cancer hyperproliferative cell disorders, and infections. The invention further relates to vectors comprising polynucleotides encoding the EphA2-BiTEs of the invention, host cells transformed therewith, and their use in the production of said EphA2-BiTEs.Type: ApplicationFiled: December 21, 2006Publication date: February 21, 2008Inventors: Scott Hammond, Peter Kiener, Elizabeth Bruckheimer, Michael Kinch, Shannon Roff, Ralf Lutterbuese, Petra Lutterbuese, Bernd Schlereth, Patrick Baeuerle, Peter Kufer
-
Patent number: 7332168Abstract: The present invention relates to a composition for the selective elimination of autoreactive B-cells comprising at least one (poly)peptide construct consisting of at least two domains wherein one of said domains comprises an autoreactive antigen or (a) fragments(s) thereof specifically recognized by the Ig receptors of said autoreactive B-cells and wherein one of said domains comprises an effector molecule capable of interacting with and/or of activating NK-cells, T-cells, macrophages, monocytes and/or granulocytes and/or capable of activating the complement system.Type: GrantFiled: August 22, 2001Date of Patent: February 19, 2008Assignee: Micromet AGInventors: Marcel Zocher, Patrick Bäeuerle, Torsten Dreier
-
Patent number: 7323440Abstract: The present invention relates to a (poly)peptide construct consisting of at least two domains of at least two pluralities of domains wherein one of said domains or pluralities of domains comprises a de-immunized autoreactive antigen or (a) fragment(s) thereof specifically recognized by the Ig receptors of an autoreactive B-cells and wherein a/the further domain or plurality of domains comprises an effector molecule capable of interacting with and/or of activating NK-cells, T-cells, macrophages, monocytes and/or granulocytes. Preferably, said (poly)peptide construct consisting of at least two domains comprises a de-immunized autoreactive antigen or (a) fragment which is MOG or (a) fragment(s) thereof and a second domain comprising an effector molecule is an anti-CD3 receptor or an Fc-part of an immunoglobulin. The invention also relates to compositions comprising the compounds of the invention.Type: GrantFiled: February 12, 2003Date of Patent: January 29, 2008Assignee: Micromet AGInventors: Marcel Zocher, Torsten Dreier, Patrick Baeuerle
-
Publication number: 20070249529Abstract: The present invention relates to compositions comprising polypeptides, especially polypeptides capable of specifically binding predetermined antigens. The polypeptide in the composition comprises at least two antigen binding sites. These at least two antigen binding sites are located on a single polypeptide chain. One of the at least two antigen binding sites specifically binds the human CD3 antigen. The polypeptide may exist in both monomeric form and multimeric form. The multimeric form of the polypeptide constitutes no more than 5% of the total weight of the combined monomeric and multimeric forms of said polypeptide.Type: ApplicationFiled: November 26, 2004Publication date: October 25, 2007Inventors: Robert Hofmeister, Nadja Prang, Andreas Wolf, Frank Hanakam, Thomas Urbig, Christian Itin, Patrick Baeuerle
-
Patent number: 7235641Abstract: The present invention discloses bispecific antibodies comprising two antibody variable domains on a single polypeptide chain, wherein a first portion of the bispecific antibody is capable of recruiting the activity of a human immune effector cell by specifically binding to an effector antigen on the human immune effector cell, the first portion consisting of one antibody variable domain, and a second portion of the bispecific antibody specifically binding to a target antigen other than the effector antigen, the target antigen on a target cell other than the human immune effector cell, the second portion comprising one antibody variable domain.Type: GrantFiled: December 22, 2003Date of Patent: June 26, 2007Assignee: Micromet AGInventors: Peter Kufer, Meera Berry, Patrick Baeuerle, Christian Itin
-
Patent number: 7101681Abstract: Methods for identifying modulators of nuclear hormone receptor function comprise the steps of (a) forming a mixture comprising a nuclear hormone receptor, a peptide sensor and a candidate agent, but not a natural coactivator protein of the receptor, wherein the sensor provides direct, in vitro binding to the receptor under assay conditions; (b) measuring an agent-biased binding of the sensor to the receptor; and (c) comparing the agent-biased binding with a corresponding unbiased binding of the sensor to the receptor. In particular embodiments, the sensor comprises an amphipathic alpha helix nuclear hormone interacting domain comprising a recited nuclear hormone transcriptional coactivator motif sequence, the sensor is present at sub-micromolar concentration, the binding reaction occurs in solution, the sensor comprises a fluorescent label and the measuring step comprises detecting fluorescence polarization of the label.Type: GrantFiled: September 30, 1998Date of Patent: September 5, 2006Assignee: Amgen, Inc.Inventors: Kevin Lustig, Patrick Baeuerle, Holger Beckmann, Jin-Long Chen, Bei Shan
-
Publication number: 20060062780Abstract: The present invention relates to a (poly)peptide construct consisting of at least two domains of at least two pluralities of domains wherein one of said domains or pluralities of domains comprises a de-immunized autoreactive antigen or (a) fragment(s) thereof specifically recognized by the Ig receptors of an autoreactive B-cells and wherein a/the further domain or plurality of domains comprises an effector molecule capable of interacting with and/or of activating NK-cells, T-cells, macrophages, monocytes and/or granulocytes. Preferably, said (poly)peptide construct consisting of at least two domains comprises a de-immunized autoreactive antigen or (a) fragment which is MOG or (a) fragment(s) thereof and a second domain comprising an effector molecule is an anti-CD3 receptor or an Fc-part of an immunoglobulin. The invention also relates to compositions comprising the compounds of the invention.Type: ApplicationFiled: February 12, 2003Publication date: March 23, 2006Inventors: Marcel Zocher, Torsten Dreier, Patrick Baeuerle
-
Publication number: 20060063709Abstract: Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transcription of Ig genes. In particular, NF-kB, the gene encoding NF-kB, IkB and the gene encoding IkB and uses therefor.Type: ApplicationFiled: January 4, 2002Publication date: March 23, 2006Inventors: David Baltimore, Ranjan Sen, Phillip Sharp, Harinder Singh, Louis Staudt, Jonathan LeBowitz, Albert Baldwin, Roger Clerc, Lynn Corcoran, Patrick Baeuerle, Michael Lenardo, Chen-Ming Fan, Thomas Maniatis
-
Publication number: 20050136050Abstract: The present invention discloses bispecific antibodies comprising two antibody variable domains on a single polypeptide chain, wherein a first portion of the bispecific antibody is capable of recruiting the activity of a human immune effector cell by specifically binding to an effector antigen on the human immune effector cell, the first portion consisting of one antibody variable domain, and a second portion of the bispecific antibody specifically binding to a target antigen other than the effector antigen, the target antigen on a target cell other than the human immune effector cell, the second portion comprising one antibody variable domain.Type: ApplicationFiled: December 22, 2003Publication date: June 23, 2005Inventors: Peter Kufer, Meera Berry, Patrick Baeuerle, Christian Itin
-
Publication number: 20040214757Abstract: Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transcription of Ig genes. In particular, NF-kB, the gene encoding NF-kB, IkB and the gene encoding IkB and uses therefor.Type: ApplicationFiled: January 4, 2002Publication date: October 28, 2004Inventors: David Baltimore, Ranjan Sen, Phillip A. Sharp, Harinder Singh, Louis Staudt, Jonathan H. LeBowitz, Albert S. Baldwin, Roger G. Clerc, Lynn M. Corcoran, Patrick A. Baeuerle, Michael J. Lenardo, Chen-Ming Fan, Thomas P. Maniatis
-
Patent number: 6555326Abstract: Methods for identifying modulators of nuclear hormone receptor function comprise the steps of (a) forming a mixture comprising a nuclear hormone receptor, a peptide sensor and a candidate agent, but not a natural coactivator protein of the receptor, wherein the sensor provides direct, in vitro binding to the receptor under assay conditions; (b) measuring an agent-biased binding of the sensor to the receptor; and (c) comparing the agent-biased binding with a corresponding unbiased binding of the sensor to the receptor. In particular embodiments, the sensor comprises an amphipathic alpha helix nuclear hormone interacting domain comprising a recited nuclear hormone transcriptional coactivator motif sequence, the sensor is present at sub-micromolar concentration, the binding reaction occurs in solution, the sensor comprises a fluorescent label and the measuring step comprises detecting fluorescence polarization of the label.Type: GrantFiled: November 21, 1997Date of Patent: April 29, 2003Assignee: Tularik Inc.Inventors: Kevin Lustig, Patrick Baeuerle, Holger Beckmann, Jin-Long Chen, Bei Shan
-
Patent number: 6410516Abstract: Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transription of Ig genes. In particular, NF-kB, the gene encoding NF-kB, IkB and the gene encoding IkB and uses therefor.Type: GrantFiled: June 5, 1995Date of Patent: June 25, 2002Assignees: President & Fellows of Harvard College, Massachusetts Institute of Technology, Whitehead Instittue for Biomedical ResearchInventors: David Baltimore, Ranjan Sen, Phillip A. Sharp, Harinder Singh, Louis Staudt, Jonathan H. Lebowitz, Albert S. Baldwin, Jr., Roger G. Clerc, Lynn M. Corcoran, Patrick A. Baeuerle, Michael J. Lenardo, Chen-Ming Fan, Thomas P. Maniatis
-
Patent number: 6232068Abstract: The present invention relates to anti-heteronucleic acid antibodies and their uses for detection of RNA-DNA duplexes on arrays. The invention provides a method for detection of total cellular RNA hybridization on microarrays, thus obviating the need for isolation of the poly(A)+ fraction.Type: GrantFiled: January 22, 1999Date of Patent: May 15, 2001Assignees: Rosetta Inpharmatics, Inc., Tularik Inc.Inventors: Peter S. Linsley, Patrick Baeuerle
-
Patent number: 6172195Abstract: The invention provides methods and compositions relating to IKAP proteins which regulate cellular signal transduction and transcriptional activation, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IKAP encoding nucleic acids or purified from human cells. The invention provides isolated IKAP hybridization probes and primers capable of specifically hybridizing with the disclosed IKAP genes, IKAP-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.Type: GrantFiled: April 6, 1999Date of Patent: January 9, 2001Assignee: Tularik Inc.Inventors: Lucie Cohen, Patrick Baeuerle
-
Patent number: 6150090Abstract: Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transription of Ig genes. In particular, NF-kB, the gene encoding NF-kB, IkB and the gene encoding IkB and uses therefor.Type: GrantFiled: June 5, 1995Date of Patent: November 21, 2000Assignees: Massachusetts Institute of Technology, Whitehead Institute, President and Fellows of Harvard CollegeInventors: David Baltimore, Ranjan Sen, Phillip A. Sharp, Harinder Singh, Louis Staudt, Jonathan H. LeBowitz, Albert S. Baldwin, Jr., Roger G. Clerc, Lynn M. Corcoran, Patrick A. Baeuerle, Michael J. Lenardo, Chen-Ming Fan, Thomas P. Maniatis
-
Patent number: 6090542Abstract: Inhibition of the transcription of genes in higher eukaryotic cells by inhibiting the activation of NF-KB, wherein the cells are treated with substances which specifically inhibit the proteolytic degradation of IKB-.alpha. directly or indirectly. Process for screening substances which inhibit NF-KB activation by inhibiting the proteolytic degradation of IKB-.alpha.. Use of the substances for treating pathological conditions which can be traced back to undesirable gene expression controlled by NF-KB.Type: GrantFiled: January 22, 1996Date of Patent: July 18, 2000Assignee: Boehringer Ingelheim International GmbHInventors: Patrick Baeuerle, Thomas Henkel
-
Patent number: 5891719Abstract: The invention provides methods and compositions relating to IKAP proteins which regulate cellular signal transduction and transcriptional activation, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IKAP encoding nucleic acids or purified from human cells. The invention provides isolated IKAP hybridization probes and primers capable of specifically hybridizing with the disclosed IKAP genes, IKAP-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.Type: GrantFiled: November 16, 1997Date of Patent: April 6, 1999Assignee: Tularik Inc.Inventors: Lucie Cohen, Patrick Baeuerle
-
Patent number: 5804374Abstract: Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transription of Ig genes. In particular, NF-kB, the gene encoding NF-kB, IkB and the gene encoding IkB and uses therefor.Type: GrantFiled: April 6, 1995Date of Patent: September 8, 1998Assignees: Massachusetts Insti. Technology, Whitehead Insti., Pres. and Fellow of Harvard CollegeInventors: David Baltimore, Ranjan Sen, Phillip A. Sharp, Harinder Singh, Louis Staudt, Jonathan H. LeBowitz, Albert S. Baldwin, Jr., Roger G. Clerc, Lynn M. Corcoran, Patrick A. Baeuerle, Michael J. Lenardo, Chen-Ming Fan, Thomas P. Maniatis